SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Ahlberg Lucia 1959 )
 

Search: WFRF:(Ahlberg Lucia 1959 ) > High relapse rate o...

  • Kozlowski, Piotr,1969-Region Örebro län,Hematology Section, Department of Medicine, Örebro University Hospital, Örebro, Sweden (author)

High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden

  • Article/chapterEnglish2014

Publisher, publication year, extent ...

  • 2014-02-21
  • Wiley,2014

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:3b5a8885-dd91-4159-a389-0c85ce3dfaec
  • https://lup.lub.lu.se/record/4438856URI
  • https://doi.org/10.1111/ejh.12269DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-48486URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:128686917URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-88943URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-224711URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-106674URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Background Hyper-CVAD is widely used to treat acute lymphoblastic leukemia (ALL) and aggressive lymphomas. This multicenter, population-based study assessed the efficacy of Hyper-CVAD as first-line therapy in patients with T-cell ALL (T-ALL). Patients and methods Between October 2002 and September 2006, 24 patients were diagnosed with T-ALL in Sweden; 19 were eligible for treatment with the protocol. Results The median age was 32yr (range 18-72yr). Complete remission (CR) was obtained in 17 of 19 (89%) patients, and the treatment was relatively well tolerated. Allogeneic stem cell transplantation (SCT) was recommended in high-risk disease and was performed in four patients upfront. Two- and 5-yr leukemia-free survivals (LFS) in 17 patients with CR achievement were identical, at 29% (95% confidence interval [CI]: 8-51). Two- and 5-yr overall survival (OS) in whole cohort was 63% (95% CI: 42-85) and 47% (95% CI: 26-69), respectively. The 5-yr LFS for 15 patients who did not receive allogeneic SCT upfront were 20% (95% CI: 0-40), although 14 of 15 completed the protocol (eight cycles). Relapse occurred in 2 of 4 upfront-transplanted patients and in 12 of 15 patients treated with chemotherapy alone, six of whom received allogeneic SCT in CR2. Age >= 35yr influenced OS negatively in univariate analysis (HR 5.1, 95% CI: 1.55-16.7). Conclusions Hyper-CVAD treatment resulted in a high CR rate and appeared safe, but it showed poor efficacy at preventing relapse. Therefore, this treatment is no longer recommended for adults with T-ALL in Sweden.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Åström, Maria,1959-Region Örebro län,Hematology Section, Department of Medicine, Örebro University Hospital, Örebro, Sweden(Swepub:oru)mram (author)
  • Ahlberg, LuciaÖstergötlands Läns Landsting,Linköpings universitet,Avdelningen för kliniska vetenskaper,Hälsouniversitetet,Hematologiska kliniken US(Swepub:liu)lucah64 (author)
  • Bernell, PerKarolinska University Hospital, Stockholm, Sweden (author)
  • Hulegardh, ErikDepartment of Hematology and Coagulation, Sahlgrenska University, Göteborg, Sweden (author)
  • Hägglund, HansUppsala universitet,Karolinska Institutet,Hematologi,Karolinska University Hospital, Sweden(Swepub:uu)hanha689 (author)
  • Karlsson, KarinLund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Department of Hematology, Skåne University Hospital, Lund, Sweden(Swepub:lu)stem-kka (author)
  • Markuszewska-Kuczymska, AlicjaUmeå universitet,Onkologi,University Hospital, Sweden(Swepub:umu)alma0043 (author)
  • Tomaszewska-Toporska, BeataDepartment of Hematology, Skåne University Hospital, Lund, Sweden (author)
  • Smedmyr, BengtUppsala universitet,Hematologi,Uppsala University, Sweden(Swepub:uu)besme236 (author)
  • Amini, Rose-MarieUppsala universitet,Molekylär och morfologisk patologi,Uppsala University, Sweden(Swepub:uu)roseamin (author)
  • Hallböök, HeleneUppsala universitet,Hematologi,Uppsala University, Sweden(Swepub:uu)helehall (author)
  • Region Örebro länHematology Section, Department of Medicine, Örebro University Hospital, Örebro, Sweden (creator_code:org_t)

Related titles

  • In:European Journal of Haematology: Wiley92:5, s. 377-3811600-06090902-4441

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view